Printer Friendly

Spectrum of haemoglobinopathies diagnosed by cation exchange-HPLC & modulating effects of nutritional deficiency anaemias from north India.

The laboratory diagnosis of thalassaemias and other haemoglobinopathies can be achieved by a step-wise approach starting with a detailed clinical history, thorough haematologic evaluation [including haemoglobin level, complete blood count (CBC), reticulocyte count, and red blood cell (RBC) morphology], protein based analytic methods [alkaline and acid Hb-electrophoresis, isoelectric focusing (IEF) and high performance liquid chromatography (HPLC)] and nucleic acid based methods [such as polymerase chain reaction (PCR), reverse transcriptase (RT)-PCR, and sequencing of genomic DNA] (1,2). Family studies also play a crucial role in clinching the diagnosis in certain problematic cases.

The aim of the present study was to evaluate the role of cation exchange HPLC (CE-HPLC) along with adjunctive tests as needed in the diagnosis of thalassaemias/haemoglobinopathies and to see the profile of these in the indigenous population. It is especially important to validate the role of HPLC, as it is less labour intensive with rapid turn around time and better reproducibility compared to Hb electrophoresis. Moreover, it can replace tedious procedures like estimation of foetal haemoglobin and [HbA.sub.2] quantitation by column chromatography. We also tried to evaluate the effect of nutritional deficiency anaemia, especially iron deficiency anaemia (IDA), on the level of [HbA.sub.2] in non-thalassaemia subjects and if the change was sufficient enough to confound the diagnosis of [beta]-thalassaemia trait.

Material & Methods

This was a prospective study carried out in the department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, over 7 months duration from January to July 2008. Consecutive 800 blood samples sent for suspected thalassaemia/ haemoglobinopathy work-up were analyzed by CE-HPLC (BioRad laboratories, California, USA) using Variant [beta]-thal short program. This included mainly transfusion requiring children and adults, antenatal cases and their family members. Cases with nutritional deficiency anaemia, where a co-existent thalassaemia/ haemoglobinopathy was suspected, were also screened. No absolute exclusion criteria were used but for patients requiring blood transfusions, sampling was deferred for at least 4 wk after or just before next transfusion. Written consent was taken from all patients for using their sample for research purpose. About 1-2 ml of blood sample was collected in EDTA vial and was analyzed in automated cell counter (Sysmex XT 1800i; Kobe, Japan) for complete blood counts. Samples were stored at 4-8[degrees]C and were analyzed in batches within one week. Wherever required, haemolysate preparation was run on agarose gel electrophoresis at alkaline pH of 8.6 from the same sample. The presence of HbH was confirmed by using brilliant cresyl blue test for HbH inclusions. IDA was diagnosed on the basis of serum iron levels, total iron binding capacity, transferrin saturation and serum ferritin levels. Patients suspected of megaloblastic anaemia on account of a raised mean corpuscular volume (MCV>110fl), were confirmed mostly by bone marrow examination or serum vitamin B12/folic acid assay in some of the cases. This was a single time study and no follow up was done.

Continuous variables were expressed as mean[+ or -]SD. Categorical variables were expressed as frequencies and percentages. Two sample t-test was applied for significance of association between continuous variables. All statistical analysis was performed using STATA 9.1 statistical software (Statacorp, College Station, Texas, USA).


Samples: Of the 800 subjects tested, 259 (32.4%) were males and 541 (67.6%) were females. The age range of patients was from 5 months to 77 yr with a median age of 25 yr (mean age 24.2 yr). The preponderance of young female patients was due to antenatal patients coming for routine HPLC work-up. Of the total cases, 553 (69.1%) were found to have normal HPLC pattern. Analysis of the retention times and %Hb for [HbA.sub.0], [HbA.sub.2], and HbF showed no significant difference with regard to column and/or reagent changes. In this study the influence of haemoglobin stability testing and patient ethnicity were not included.

Retention times and proportions of haemoglobin variants: The number of observations, %Hb fraction, haemogram findings and the type of Hb variants encountered are shown in the Table. Separation of cases into transfused and not transfused was not done. Although the sampling was done with due precaution, the HbA and HbF levels shown in the Table may not be truly representative particularly in the thal major/intermedia group due to frequent transfusion requirement in some of them. As expected, out of 800 samples, [beta]-thalassaemia trait was detected most frequently i.e., in 145 (18.1%) cases with cut-off value of [HbA.sub.2] being >3.9 per cent3 and [beta]-thalassaemia major/ [beta]-thalassaemia intermedia was seen in 23 (2.9%) cases. Apart from [beta]-thalassaemia, nine additional variants were encountered; HbS (2.8%), HbE (2.5%) and HbD-Punjab (1.1%) were the most common variants present. Other variants included HbQ-India, Hb-Lepore, [delta][beta]-thal/HPFH, HbD-Iran, HbJ-Meerut, Hb-H disease. Possibility of an [alpha]-thalassemia trait could be suggested in 11 (1.4 %) cases on the basis of red cell indices and the levels of [HbA.sub.2] [2.2 ([+ or -] 0.3)%] which were significantly (P<0.001) lower than normal population 2.9 [+ or -] 0.4. However, results of further molecular testing were not available for a definite conclusion.

The retention time alone [n = 4 (i.e., HbS, HbD-Punjab, HbQ-India, HbH)] or in conjunction with %Hb [n = 3 (i.e., HbJ-Meerut, HbE, [delta][beta]-thal trait/HPFH)] or with the peak characteristics [n = 2 (HbD-Iran, HbLepore)] could identify all the 9 haemoglobin variants seen. However, Hb-electrophoresis was resorted to in many doubtful cases to confirm the diagnosis. Family HPLC screening also helped in some difficult cases especially in double heterozygous states. Role of family studies has been emphasized by other studies also4. Various normal and variant haemoglobins encountered were as follows:

Haemoglobin variants with retention times <1.0 min: One case of HbH disease was detected, which was confirmed by fast-moving band on electrophoresis and a positive HbH inclusion test.

Haemoglobin variants with retention times in the p1 window (0.63-0.85 min): No haemoglobin variants were detected in this window.

Haemoglobin variants with retention times in the F window (0.98-1.20 min): At least seven haemoglobin variants (four [beta]-and three a-variants) are expected to elute in this window, all in quantities >10 per cent (5). However, most of our patients with high Hb in the F window were mostly homozygous [beta]-thalassaemia patients or double heterozygous [beta] thalassaemia/ haemoglobinopathy patients confirmed by Hb-electrophoresis and family studies. Four cases revealed high HbF levels in the range of 1-10 per cent, two of whom had haemolytic anaemia (Coombs test positive) and the other two were pregnant patients. No variant was found in this window.

Haemoglobin variants with retention times in the p2 window (1.24-1.40 min): HbA1c elutes in the P2 window. When the elution peak was >7 per cent of the total haemoglobin, the patient records were checked for indication of diabetes. We came across two cases of known diabetics with a mean P2 value of 13.2 per cent and retention time of 1.28 min. No haemoglobin variants were detected in this window.

Haemoglobin variants with retention times in the p3 window (1.40-1.90 min): A previous study has found nine haemoglobin variants (four [alpha]-and five [beta]-variants) with elution peaks in the P3 window (6). We found a single case of possible HbJ-Meerut which was suspected based on its retention time (1.73 min) and Hb-percentage (26.5%).

Haemoglobin variants with retention times in the [A.sub.0] window (1.90-3.10 min): Six haemoglobin variants (two [alpha]-and four [beta]-variants) have been reported in the [A.sub.0] window (6). No such variant was found in our study.

Haemoglobin variants with retention times in the [A.sub.2] window (3.30-3.90 min): Four haemoglobin variants had elution peaks in the A2 window-Hb [A.sub.2], HbE, HbLepore and HbD Iran. The retention times and %Hb for [HbA.sub.2] (3.65 min) and HbE (3.73 min) were significantly different (P<0.001). The retention time forHbD-Iran (3.62 min) appeared to be different from those of HbE (3.73 min) and Hb Lepore (3.5 min). However, statistical analysis could not be done because of less number of cases. In addition, the mean %Hb of HbD-Iran (40.6%) was greater than either of these Hb (HbE-27.8%, Hb-Lepore-16.4%). So the values more than 40 per cent in Hb [A.sub.2] window with a different retention time made us suspect Hb D Iran which was confirmed by starch agarose gel electrophoresis where a band in the SDG region was seen Hb Lepore could be differentiated and identified based on its retention time, %Hb and the characteristic hump on the downward slope of the elution peak (6). [delta][beta]-thalassaemia trait presented with a low [HbA.sub.2] (2.8%) and mildly elevated HbF levels (13.3%).

Haemoglobin variants with retention times in the D window (3.90-4.30 min): Only one haemoglobin variant; HbD-Punjab, with retention times of 4.07 min, was identified in D window. The mean [HbA.sub.2] values for HbD-Punjab trait (1.7 [+ or -] 0.4%) were significantly lower (P<0.001) than the range for [HbA.sub.2] in the normals.

Haemoglobin variants with retention times in the S window (4.30-4.70 min): Only HbS variant, with retention times of 4.41 min, was seen in this window. The mean [HbA.sub.2] value for HbS trait (3.3 [+ or -] 0.3%) was significantly higher (P<0.001) than the range for [HbA.sub.2] in the normal samples. A new abnormal haemoglobin Hb D Agri with 2 amino acid substitutions in the same [beta] globin chain [[beta]9 (A6) Ser [right arrow] Tyr, P121(GH-4) Glu [right arrow] Gln] has been reported in India which can be mistaken for HbS based on HPLC alone (7). However, a negative sickling and solubility test should raise a suspicion followed by molecular studies for confirmation.

Haemoglobin variants with retention times in the unknown window (4.70-4.90 min): Three cases of HbQ-India were identified with a retention time of 4.7 [+ or -] 0.01 min and mean %Hb of 18.5 [+ or -] 0.2%.

Haemoglobin variants with retention times in the C window (4.90-5.30 min): No haemoglobin variant was detected in this window.

Effect of iron deficiency anaemia on [HbA.sub.2] levels: The patients with normal HPLC pattern (total 203 in number where iron studies were available) were divided in two groups depending upon their iron profile. The levels of [HbA.sub.2] for 186 patients with IDA (2.74 [+ or -] 0.34%) was found to be significantly lower (P=0.004) than the 17 patients with normal iron profile (3.03 [+ or -] 0.26%). However; there was no significant difference in the levels of [HbA.sub.2] for 25 [beta]-thalassaemia trait patients, 18 with concomitant IDA (5.49 [+ or -] 0.52%) and 7 without IDA (5.09 [+ or -] 0.58%).

Effect of megaloblastic anaemia on [HbA.sub.2] levels: The patients with normal HPLC were divided in two groups depending upon their MCV values (>110fl) and confirmed by further testing. The 19 patients with megaloblastic anaemia showed [HbA.sub.2] levels (3.32 [+ or -] 0.56%) which was significantly higher (P<0.001) than the [HbA.sub.2] levels (2.89 [+ or -] 0.37%) of normal cases with MCV<110fl.


HPLC has been shown to be a sensitive, specific, and reproducible alternative to electrophoresis. With automation and quantitative power, it appears to be a sensitive and accurate technique for direct identification and quantification of normal and abnormal haemoglobin fractions (8-13). Different reports have addressed the precision of the retention times obtained with stored normal (14) and abnormal samples (8,9). There are a few studies from India which evaluated and emphasized the role of HPLC for diagnosis of thalassaemia and various haemoglobinopathies (3,15).

In this study, apart from [beta]-thalassaemia, nine additional variants were encountered with various incidences; HbS, HbE and HbD-Punjab being the most common variants present. The percentage of variant Hb can generally be the initial predictor whether the detected variant is an [alpha]-or [beta]-variant. In our study, all the a-variants had mean %Hb values <27 per cent, whereas among the [beta]-variants, all had mean %Hb values >35 per cent except for HbE (27.8 [+ or -] 3.4). The lower levels of HbE compared to other P-chain structural variants could be attributed to HbE being a thalassaemic haemoglobinopathy with unstable m-RNA (16). In addition, one patient with significantly lower level of HbE (20.5%) was found to have concomitant [alpha]-thalassaemia trait confirmed by DNA analysis.

HbBarts, HbH and [HbF.sub.1] (the acetylated form of HbF) were not included in the chromatogram report as HPLC software did not integrate elution peaks that occurred at < 0.63 min. Therefore, these elution peaks were detected only by visual analysis of the plot. The elution peak characteristic in addition to the retention time can be used to identify certain haemoglobin variants, e.g., in [HbA.sub.2] window; Hb-Lepore shows a characteristic hump on the downward slope in comparison to HbE, whereas HbD Iran shows a broad based curve which does not touch the baseline as against HbE. Joutovsky et al (6) found statistically significant difference amongst the retention times of different normal and variant haemoglobins within the same retention windows.

Apart from the various variant haemoglobins, the percentages of Hb F and [HbA.sub.2] also have important diagnostic implications. Along with the cases of homozygous [beta]-thalassaemia, elevated HbF levels were encountered in sickle cell disease, various double heterozygous states, [delta][beta]-thalassaemia trait/ HPFH confirmed by family studies. In addition, some cases (n= 4) showed isolated raised HbF, where no other abnormality related to haemoglobinopathy was found and family study was negative. Such cases were attributed to pregnancy (2 cases) or haemolytic anemia (2 cases). [HbA.sub.2] levels may vary with unrelated haemoglobinopathies as well. HbD-Punjab trait was associated with decreased [HbA.sub.2] (1.4-2.6%) levels, confirming previous reports where a similar range (0.9-2.5%) was reported (17,18). It was postulated that the decrease in [HbA.sub.2] may be attributable to either coelution with the [HbA.sub.0] or the HbD-Punjab peaks due to integration error or the mutation itself influencing the amount of [delta]-chain. The mean values of [HbA.sub.2] for HbS trait has been reported to be elevated in previous reports. The reason may be HbS adducts (carbamylated and glycated) coeluting with [HbA.sub.2] (19). In our study, [HbA.sub.2] was found to be significantly higher in HbS trait cases than the range for [HbA.sub.2] in the normals.

HPLC was also able to separately identify two haemoglobin variants of HbD family; HbD-Iran and HbD-Punjab. Both exhibited identical electrophoretic mobilities but eluted in [A.sub.2] and D windows respectively on HPLC. These situations are clinically important because HbD-Punjab produces a significant sickling disorder when present in a double heterozygous HbDHbS form; whereas HbD-Iran is clinically benign (20,21). The misdiagnosis of HbD-Iran as HbD-Punjab based solely on Hb-electrophoresis or as HbE based solely on Hb-HPLC, where the subtle difference in %Hb or retention time is disregarded, may lead to incorrect genetic counselling in addition to undue anxiety for the family.

The patients with IDA (with a normal HPLC) showed significantly lower levels of [HbA.sub.2] than the patients with normal iron profile as reported by others also (22). Although previous studies suggest a significant reduction in [HbA.sub.2] levels in thalassaemia trait patients associated with IDA (22); there was no significant difference in the levels of [HbA.sub.2] for 25 thal trait patients with or without IDA in our study. Similar observation has been made by Madan et al (23). In fact, the level of [HbA.sub.2] was slightly higher in the cases with concomitant

IDA than without IDA. It is difficult to render any definite explanation for this discrepant observation especially since routine mutation analysis for these cases were not carried out for the type of mutations. However, the implication that can possibly be derived by this finding is that concomitant iron deficiency in [beta]-thalassaemia trait may not cause significant lowering of [HbA.sub.2] where it may be missed. Patients with megaloblastic anaemia and normal HPLC findings, showed significantly higher [HbA.sub.2] levels than the normals as shown earlier (22). The importance of nutritional deficiencies on the levels of [HbA.sub.2] is mainly in the patients with borderline raised [HbA.sub.2] levels of 3.5-3.9 per cent. There are several causes of borderline [HbA.sub.2] including [beta]-thalassaemia trait with silent mutations, [alpha]-triplication and IDA. A recent study has reported 22.9 per cent positivity for a molecular defect in the [beta]-, [delta]-or [alpha]-globin genes among 410 subjects with borderline [HbA.sub.2] values of 3.1-3.9 per cent (24).

The present findings show HPLC as an excellent, powerful diagnostic tool for the direct identification of haemoglobin variants with a high degree of precision in the quantification of normal and abnormal haemoglobin fractions. CE-HPLC ([beta]-thal short program) may be a valuable tool in rapid diagnosis of a varied spectrum of haemoglobinopathies. It is diagnostic in most cases and only a few require other modalities for validation. Retention time and percentage of variant haemoglobin can provide important clues in differentiating variant haemoglobins eluting in the same window. Iron deficiency anaemia causes significant lowering of [HbA.sub.2] values and megaloblastic anaemia causes significant elevation of [HbA.sub.2] values in patients with normal HPLC. [HbA.sub.2] in the borderline range needs further evaluation especially for silent mutations, [alpha]-thalassaemia and coexisting nutritional deficiency.

Received March 12, 2009


(1.) Working Party of the General Hematology Task Force of the British Committee for Standards in Hematology. Guideline: the laboratory diagnosis of hemoglobinopathies. Br J Hematol 1998; 101 : 783-92.

(2.) Bain BJ. Hemoglobinopathy diagnosis, 1st ed. Oxford: Blackwell Science; 2001.

(3.) Tyagi S, Saxena R, Choudhry VP. HPLC--how necessary is it for haemoglobinopathy diagnosis in India? Indian J Pathol Microbiol 2003; 46 : 390-3.

(4.) Rangan A, Handoo A, Sinha S, Saxena R, Verma IC, Kumar S, et al. Utility of family studies in diagnosing abnormal hemoglobins/thalassemic states. Indian J Pediatr 2009; 76 : 615-21.

(5.) Hardison RC, Chui DHK, Giardine B, Riemer C, Patrinos GP, Anagnou N, et al. HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mut 2002; 19 : 225-33.

(6.) Joutovsky A, Hadzi-Nesic J, Nardi MA. HPLC retention time as a diagnostic tool for hemoglobin variants and hemoglobinopathies: A study of 60000 samples in a clinical diagnostic laboratory. Clin Chem 2004; 50 : 1736-47.

(7.) Colah RB, Wadia M, Surve R, Nadkarni A, Phanasgaonkar S, Gorakshakar A, et al. Hb D Agri [ b9 (A6) Ser [R] Tyr, b 121 (GH-4) Glu [R] Gln]: A new Indian hemoglobin variant with two amino acid substitutions in the same beta chain. Hemoglobin 2001; 25 : 317-21.

(8.) Ou CN, Rognerud CL. Diagnosis of hemoglobinopathies: electrophoresis vs. HPLC. Clin Chim Acta 2001; 313 : 187-94.

(9.) Riou J, Godart C, Didier H, Mathis M, Bimet C, Bardakdjian-Michau J, et al. Cation-exchange HPLC evaluated for presumptive identification of hemoglobin variants. Clin Chem 1997; 43 : 34-9.

(10.) Eastman JW, Wong R, Liao CL, Morales DR. Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies. Clin Chem 1996; 42 : 704-10.

(11.) Eastman JW, Lorey F, Arnopp J, Currier RJ, Sherwin J, Cunningham G. Distribution of hemoglobin F, A, S, C, E and D quantities in 4 million newborn screening specimens. Clin Chem 1999; 45 : 683-5.

(12.) Mario N, Baudin B, Aussel C, Giboudeau J. Capillary isoelectric focusing and high-performance cation-exchange chromatography compared for qualitative and quantitative analysis of hemoglobin variants. Clin Chem 1997; 43 : 213-742.

(13.) Fucharoen S, Winichagoon P, Wisedpanichkij R, Sae-Ngow B, Sriphanich R, Oncoung W, et al. Prenatal and postnatal diagnoses of thalassemias and hemoglobinopathies by HPLC. Clin Chem 1998; 44 : 740-8.

(14.) Mario N, Baudin B, Aussel C, Giboudeau J. Capillary isoelectric focusing and high-performance cation-exchange chromatography compared for qualitative and quantitative analysis of hemoglobin variants. Clin Chem 1997; 43 : 2137-42.

(15.) Colah RB, Surve R, Sawant P, D'Souza E, Italia K, Phanasgaonkar S, et al. HPLC studies in hemoglobinopathies. Indian J Pediatr 2007; 74 : 657-62.

(16.) Pignatti CB, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, editors. Wintrobes clinical hematology, 11th ed. Philedelphia: Lippincott Williams and Wilkins; 2004. p. 1319-65.

(17.) Cotton F, Gulbis B, Hansen V, Vertongen F. Interference of hemoglobin D in hemoglobin A2 measurement by cation-exchange HPLC. Clin Chem 1999; 45 : 1317-8.

(18.) Dash S. [HbA.sub.2] in subjects with HbD. Clin Chem 1998; 44 : 2381-2.

(19.) Suh DD, Kraus JS, Bures K. Influence of hemoglobin S adducts on hemoglobin A2 quantification by HPLC. Clin Chem 1996; 42 : 1113-4.

(20.) Nagel RL, Steinberg MH. Hemoglobin SC disease and HbC disorders. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. New York: Cambridge University Press; 2001. p. 756-85.

(21.) Steinberg MH. Compound heterozygous and other sickle hemoglobinopathies. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. New York: Cambridge University Press; 2001. p. 786-810.

(22.) Alperin JB, Dow PA, Petteway MB. Hemoglobin A2 levels in health and various hematologic disorders. Am J Clin Pathol 1977; 67 : 219-26.

(23.) Madan N, Sikka M, Sharma S, Rusia U. Phenotypic expression of hemoglobin A2 in beta-thalassemia trait with iron deficiency. Ann Hematol 1998; 77 : 93-6.

(24.) Giambona A, Passarello C, Vinciguerra M, Li Muli R, Teresi P, Anza M, et al. Significance of borderline hemoglobin A2 values in an Italian population with a high prevalence of b-thalassemia. Haematologica 2008; 93 :1380-4.

Seema Rao, Rakhee Kar, Sanjeev Kumar Gupta, Anita Chopra & Renu Saxena

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India

Reprint requests: Dr Seema Rao, E-28, Ayurvigyan Nagar, August Kranti Marg, New Delhi 110 049, India

Table. Relevant laboratory parameters in relation to normal and
abnormal haemoglobin variants

 No. of Hb MCV
Presumptive HPLC Diagnosis cases (%) (g/dl) (fl)

Normal 553 9.6 83.3
 (69.1) (2.7) (10.7)

[beta]-Thal trait 145 10.3 68.6
 (18.1) (2.1) (7.4)

[beta]-Thal major/Intermedia 23 5.4 74.9
 (2.9) (1.7) (8.5)

Sickle cell trait 11 11.6 84.3
 (1.4) (1.8) (3.4)

HbS/[beta]-thal 6 7.6 75.2
 (0.8) (1.2) (9.0)

Homozygous Sickle cell ds 4 8.3 90.5
 (0.5) (1.9) (9.7)

HbE-trait 9 11.4 82.3
 (1.1) (2.3) (4.4)

HbE/[beta]-thal 10 6.2 63.9
 (1.3) (1.1) (7.7)

Homozygous HbE ds 1 7.5 63

HbD-Punjab trait 7 8.1 70.3
 (0.9) (2.4) (16.1)

HbD/[beta]-thal 1 13.3 67.1

Double hetero HbSD ds 1 8.8 90.2

HbQ-India trait 3 12.5 80.7
 (0.4) (1.6) (7.2)

Hb-Lepore trait 1 9.9 72.2

[alpha]-thal trait 11 7.6 63.8
 (1.4) (1.9) (6.9)

[sigma][beta]-thal trait 6 11.1 69.0
 (0.8) (2.2) (7.7)

HPFH 1 11.1 73.5

HbD-Iran trait 3 7.4 64
 (0.4) (4.3) (13.7)

Hb-H disease 1 4.9 84.0

HbJ-Meerut trait 1 11.9 91.1

 RBC count
 MCH MCHC (x[10.sup.6]/
Presumptive HPLC Diagnosis (pg) (%) [micro]l)

Normal 25.1 30.6 3.82
 (4.9) (3.8) (0.8)

[beta]-Thal trait 20.5 28.3 5.06
 (2.6) (1.8) (0.9)

[beta]-Thal major/Intermedia 23.3 31.1 2.41
 (3.7) (3.2) (0.9)

Sickle cell trait 26.7 31.7 4.45
 (2.3) (2.3) (0.54)

HbS/[beta]-thal 21.8 29.2 3.49
 (2.0) (2.6) (0.6)

Homozygous Sickle cell ds 29.5 32.7 2.8
 (3.4) (0.9) (0.6)

HbE-trait 26.2 31.6 4.3
 (1.5) (1.1) (0.7)

HbE/[beta]-thal 19.3 30.1 3.2
 (2.7) (1.4) (0.54)

Homozygous HbE ds 20.4 32.3 3.68

HbD-Punjab trait 20.4 28.3 3.98
 (7.4) (3.9) (0.42)

HbD/[beta]-thal 21.1 31.5 6.29

Double hetero HbSD ds 27.8 30.9 3.16

HbQ-India trait 26.6 32.9 4.69
 (2.1) (0.4) (0.2)

Hb-Lepore trait 22.9 31.7 4.32

[alpha]-thal trait 16.8 26.3 4.66
 (2.8) (2.6) (0.9)

[sigma][beta]-thal trait 20.8 30.1 5.36
 (2.7) (0.9) (1.0)

HPFH 23.9 32.6 4.64

HbD-Iran trait 17.7 26.9 3.99
 (7.1) (4.8) (0.8)

Hb-H disease 20.7 24.6 2.3

HbJ-Meerut trait 30.1 33.1 3.95

Presumptive HPLC Diagnosis RDW-SD (%) Hb A (%) Hb F (%)

Normal 47.6 87.4 0.2
 (10.4) (4.2) (0.5)

[beta]-Thal trait 35.7 83.2 1.0
 (8.1) (2.1) (1.3)

[beta]-Thal major/Intermedia 55.3 39.2 52.5
 (14.4) (30.5) (35.2)

Sickle cell trait 45.3 52.7 2.3
 (16.2) (3.8) (3.6)

HbS/[beta]-thal 49.5 4.6 18.3
 (15.5) (1.8) (8.4)

Homozygous Sickle cell ds 66.8 8.5 18.3
 (6.6) (13.7) (8.2)

HbE-trait 41.1 61.9 1.6
 (5.8) (1.9) (3.7)

HbE/[beta]-thal 47.9 18.1 21.7
 (9.8) (22.4) (12.2)

Homozygous HbE ds 31.4 3.7 4.5

HbD-Punjab trait 42.3 55.7 0.5
 (12.5) (4.1) (0.4)

HbD/[beta]-thal 34.1 3.7 2.3

Double hetero HbSD ds 60.8 2.2 8.6

HbQ-India trait 37.9 71.5 0
 (1.1) (1.7)

Hb-Lepore trait 32.3 70.5 4.4

[alpha]-thal trait 39.0 85.9 0.3
 (11.7) (3.4) (0.4)

[sigma][beta]-thal trait 40.7 72.5 13.3
 (7.2) (2.4) (4.3)

HPFH 39.9 62.4 31.5

HbD-Iran trait 32.6 49.6 0.8
 (3.8) (1.9) (0.3)

Hb-H disease 45 87.7 0.4

HbJ-Meerut trait 45.9 65.4 0.5

 Hb[A.sub.2] Variant Hb
Presumptive HPLC Diagnosis (%) (%)

Normal 2.9

[beta]-Thal trait 5.5

[beta]-Thal major/Intermedia 3.7

Sickle cell trait 3.3 36.3
 (0.3) (4.8)

HbS/[beta]-thal 4.5 71.7
 (0.6) (5.8)

Homozygous Sickle cell ds 2.4 74.5
 (0.5) (6.7)

HbE-trait -- 27.8

HbE/[beta]-thal -- 52.3

Homozygous HbE ds -- 78.2

HbD-Punjab trait 1.7 34.6
 (0.4) (4.1)

HbD/[beta]-thal 4.7 83

Double hetero HbSD ds 3.2 41.9/41

HbQ-India trait 2.0 18.5
 (1.7) (0.2)

Hb-Lepore trait -- 16.4

[alpha]-thal trait 2.2

[sigma][beta]-thal trait 2.8

HPFH 2.7

HbD-Iran trait -- 40.6

Hb-H disease 2.2 --

HbJ-Meerut trait 2.5 26.5

All figures mentioned are mean [+ or -] SD. Two cases with high
HbAlc are not mentioned in this Table.

Hb, haemoglobin; MCV, mean cell volume; MCH, mean cell haemoglobin;
MCHC, mean cell haemoglobin concentration; RBC, red blood cell; RDW,
red cell distribution width; Thal, thalassaemia
COPYRIGHT 2010 Indian Council of Medical Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Rao, Seema; Kar, Rakhee; Gupta, Sanjeev Kumar; Chopra, Anita; Saxena, Renu
Publication:Indian Journal of Medical Research
Article Type:Report
Geographic Code:9INDI
Date:Nov 1, 2010
Previous Article:Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
Next Article:Screening for in vitro phototoxic activity of methanol extracts of Croton campestris A., Ocimum gravissimum L. & Cordia verbenaceae DC.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters